Literature DB >> 28455131

Echocardiographic pulmonary artery pressure estimation and heart failure rehospitalization burden in patients with acute heart failure.

Enrique Santas1, Rafael de la Espriella-Juan2, Anna Mollar3, Ernesto Valero3, Gema Miñana3, Juan Sanchis4, Francisco Javier Chorro3, Julio Núñez4.   

Abstract

Pulmonary hypertension (PH) is a strong predictor of mortality in patients with heart failure (HF). However, the relationship between PH, through echocardiographic pulmonary artery pressure (PASP) estimation, and the risk of HF rehospitalizations remains unclear.
METHODS: We prospectively included 2343 consecutive patients discharged for acute heart failure (AHF). PH was estimated by echocardiography through PASP determination during the index admission. Patients were categorized as follows across PASP: non-measurable, normal (≤35mmHg), mild (36-45mmHg), moderate (46-60mmHg), or severe PH (>60mmHg). Negative binomial regression method was used to evaluate the association between PASP and recurrent HF hospitalizations across preserved (HFpEF: ≥50%), mid-range (HFmrEF: 40-49%) and reduced ejection fraction (HFrEF: <40%).
RESULTS: Mean age of the cohort was 72.8±11.2years, 1187 (50.5%) were women, and 1252 (53.4%) and 410 (17.5%) showed HFpEF and HFmrEF, respectively. At a median (interquartile range) follow-up of 2.3 (0.8-4.5) years, we registered 1114 (47.6%) deaths, and 1834 HF-related rehospitalizations in 943 (40.2%) patients. After multivariable adjustment, and compared to patients with normal PASP, severe PH exhibited an independent higher risk of recurrent HF admissions only in HFpEF (IRR=1.66; 95% confidence interval (CI), 1.16-2.38; p=0.005), whereas in HFmrEF patients there was a non-significant trend to higher HF readmissions (IRR: 1.73; 95% CI, 0.85-3.55; p=0.132). Severe PH was not related with recurrent hospitalizations in HFrEF (IRR: 1.19; 95% CI, 0.66-2.14; p=0.553).
CONCLUSIONS: Echocardiography-derived PASP evaluated during an episode of AHF is related to HF readmission burden, particularly in those patients with HFpEF.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Heart failure; Hospitalizations; Pulmonary hypertension

Mesh:

Year:  2017        PMID: 28455131     DOI: 10.1016/j.ijcard.2017.04.055

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

Review 1.  Insights into the pulmonary vascular complications of heart failure with preserved ejection fraction.

Authors:  Yen-Chun Lai; Longfei Wang; Mark T Gladwin
Journal:  J Physiol       Date:  2018-12-30       Impact factor: 5.182

2.  Epidemiology and outcomes of pulmonary hypertension in the cardiac intensive care unit.

Authors:  Jacob C Jentzer; Brandon M Wiley; Yogesh N V Reddy; Christopher Barnett; Barry A Borlaug; Michael A Solomon
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2022-03-16

3.  Validity of the Seattle Heart Failure Model after heart failure hospitalization.

Authors:  Song Li; Patrick Marcus; Julio Núñez; Eduardo Núñez; Juan Sanchis; Wayne C Levy
Journal:  ESC Heart Fail       Date:  2019-03-01

4.  Improvement of Left Ventricular Ejection Fraction and Pulmonary Hypertension Are Significant Prognostic Factors in Heart Failure with Reduced Ejection Fraction Patients.

Authors:  Hee Jin Kwon; Jae Hyeong Park; Jin Joo Park; Jae Hwan Lee; In Whan Seong
Journal:  J Cardiovasc Imaging       Date:  2019-10

5.  Validation of the MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) heart failure risk score and the effect of adding natriuretic peptide for predicting mortality after discharge in hospitalized patients with heart failure.

Authors:  Sayma Sabrina Khanam; Eunhee Choi; Jung-Woo Son; Jun-Won Lee; Young Jin Youn; Junghan Yoon; Seung-Hwan Lee; Jang-Young Kim; Sung Gyun Ahn; Min-Soo Ahn; Seok-Min Kang; Sang Hong Baek; Eun-Seok Jeon; Jae-Joong Kim; Myeong-Chan Cho; Shung Chull Chae; Byung-Hee Oh; Dong-Ju Choi; Byung-Su Yoo
Journal:  PLoS One       Date:  2018-11-28       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.